Cobra Biologics and Vaccibody have entered an agreement to manufacture Vaccibody’s lead DNA vaccine candidate against HPV-induced malignancies, such as precancerous lesions found in cervical cancer. Cobra Biologics will apply its platform process to deliver a program of host strain generation, GMP cell banking, plasmid DNA production and clinical trials supply.
Vaccibody develops targeted vaccines designed to induce stronger and longer lasting immune responses using its technology platform for the tailored development of enhanced prophylactic vaccines as well as therapeutic vaccines against chronic infections and cancers.
Peter Coleman, chief executive officer of Cobra Biologics, said, “Cobra has been manufacturing plasmid therapeutics and DNA vaccines for more than 14 years and I am delighted that we are able to announce the partnership with Vaccibody. Our DNA platform process is based on Cobra’s pioneering heritage in gene therapy manufacturing and technology development that we have successfully used for over 30 customers.”
Ole Henrik Brekke, chief executive officer of Vaccibody, said, “With the significantly effective preclinical results VB 10.16 has shown, we are delighted now to take the next step towards clinical trials with Cobra Biologics as our manufacturing partner.”